drugset / Trial / NCT01670071

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

NCT01670071

Phase 4 Terminated 17 enrolled Johnson & Johnson Taiwan Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effect of oral paliperidone extended-release and oral risperidone immediate-release on cognitive function, especially the category fluency of Cognitive Abilities Screening Instrument, Chinese version (CASI C-2.0), in patients with an established diagnosis of schizophrenia.

Timeline

Start
2013-01
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 6 mg Oral
Subject Paliperidone Unknown 12 mg Oral
Comparator Risperidone Other / unclassified 3 mg Oral
Comparator Risperidone Other / unclassified 7 mg Oral

Indications